Table 2.
Drug | Organic Nanoparticle Formulation | Target System | Major Findings | Ref. |
---|---|---|---|---|
RSV |
Polymeric micelles |
PC12 cell lines |
|
[163] |
RSV | Solid lipid nanoparticles (SLN) | NCTC2544 cell lines |
|
[175] |
RSV + QUE | Liposomes | HDFa cell lines and CD-1 mice |
|
[130] |
RSV | Lipid-core nanocapsules | C6 glioma cell lines and rats implanted with C6 glioma cells |
|
[179] |
Transferrin-modified PEGylated liposomes |
Xenograft mouse model of GBM and U-87 MG cell lines |
|
[131] | |
Transferrin (Tf) modified poly ethylene glycol-poly lactic acid (PEG-PLA) nanoparticles | C6, U87 cell lines and brain-glioma-bearing rat model |
|
[159] | |
Folate-modified nanostructured lipid carriers | MCF-7 cell lines and female Wistar rats |
|
[138] | |
PTX and RSV | PEGylated liposome | MCF-7 cell lines and BALB/c nude mice |
|
[133] |
EXM/RSV | Zein nano-capsules | MCF-7, 4T1 cell lines, and female Sprague Dawley rats |
|
[162] |
RSV | Solid lipid nanoparticles | SKBR3/PR, SKBR3/PR xenograft tumor models |
|
[136] |
RSV |
Dequalinium polyethylene glycol-distearoyl Phosphatidyl ethanolamine |
Xenografted resistant A549/cDDP nude mice |
|
[132] |
RSV + CUR | Liposomes | PTEN-CaP8 cancer cell lines and B6C3F1/J mice |
|
[96] |
RSV | Poly(epsilon-caprolactone) (PCL) and poly (d,l-lactic-co-glycolic acid)-poly(ethylene glycol) conjugate (PLGA-PEG-COOH) | DU-145, PC-3, and LNCaP cell lines |
|
[124] |
DOX and RSV | PLGA nanoparticle | BALB/c nude mice and MCF-7/ADR and MDA-MB-231/ADR cell lines |
|
[151] |
RSV | PLGA-polyethylene glycol (PEG) NPs coated with chitosan | Athymic mice |
|
[152] |
RSV | Biomimetic nanocarrier | HT29 and HCT116 cell lines and C57/BL6j female nude mice |
|
[154] |
RSV | Epidermal growth factor (EGF) conjugated lipid–polymer hybrid nanoparticles | HCC827, NCIH2135, and HUVEC cell lines and BALB/c nude mice |
|
[176] |